Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFXN2T)

Drug Name
AMG 745 Drug Info
Indication
Disease Entry ICD 11 Status REF
Muscle atrophy FB32.Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMFXN2T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Growth/differentiation factor 8 (GDF-8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2495655 DMM5JAN Disuse muscle atrophy 8B61 Phase 2 [3]
PF-06252616 DMQLZOF Duchenne dystrophy 8C70 Phase 2 [3]
SAR391786 DMS1YPZ Muscle atrophy FB32.Y Phase 2 [4]
Domagrozumab DMCT08V Duchenne dystrophy 8C70 Phase 2 [5]
ACE-031 DMZ8PY0 Duchenne dystrophy 8C70 Phase 2 [6]
Stamulumab DMBCIXL Duchenne dystrophy 8C70 Phase 1/2 [3]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Growth/differentiation factor 8 (GDF-8) TTSWPH8 GDF8_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT00975104) AMG 745 in Subjects With Age-associated Muscle Loss. U.S. National Institutes of Health.
2 The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151.
3 Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
4 Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23.